Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients

This study has been completed.
Information provided by (Responsible Party):
Human Genome Sciences Inc. Identifier:
First received: November 20, 2006
Last updated: August 1, 2013
Last verified: August 2013

This is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of albumin interferon alfa 2b (alb-IFN)in combination with ribavirin compared with peginterferon alfa-2a (PEGASYS or PEG-IFNa2a) in combination with ribavirin in subjects with chronic hepatitis C, genotype 1 who are IFNa treatment naive.

Condition Intervention Phase
Chronic Hepatitis C
Drug: albumin interferon alfa-2b
Drug: peginterferon alfa-2a
Drug: Ribavirin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 3 Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b in Combination With Ribavirin Compared With Peginterferon Alfa-2a in Combination With Ribavirin in Interferon Alfa Naive Subjects With CHC Genotype 1. ACHIEVE-1

Resource links provided by NLM:

Further study details as provided by Human Genome Sciences Inc.:

Primary Outcome Measures:
  • Sustained virologic response (SVR) [ Time Frame: Week 72 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Rapid virologic response [ Time Frame: Week 4 ] [ Designated as safety issue: No ]
  • Early virologic response [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
  • Undetectable HCV RNA [ Time Frame: Week 24 and Week 48 ] [ Designated as safety issue: No ]
  • Normalization of ALT (a liver enzyme) [ Time Frame: Week 48 ] [ Designated as safety issue: Yes ]
  • Quality of life evaluation [ Time Frame: throughout the entire study ] [ Designated as safety issue: No ]
  • Safety assessments (physical exams, AE reporting, lab testing/analysis, HADS and Immunogenicity testing) [ Time Frame: Throughout the entire study ] [ Designated as safety issue: Yes ]

Enrollment: 1331
Study Start Date: December 2006
Study Completion Date: February 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
180 mcg PEG-IFNx2a every 1 week (48 doses) + Ribavirin 1000 or 1200 mg/day
Drug: peginterferon alfa-2a
180 mcg once a week for 48 weeks
Drug: Ribavirin

1000 mg/day(for subjects <75kg) or 1200 mg/day (for subjects

=,> 75kg)

Experimental: 2
900 mcg alb-IFN every 2 weeks (24 doses)+ Ribavirin 1000 or 1200 mg/day
Drug: albumin interferon alfa-2b
900 mcg or 1200mcg every two week for 48 weeks
Drug: Ribavirin

1000 mg/day(for subjects <75kg) or 1200 mg/day (for subjects

=,> 75kg)

Experimental: 3
1200 mcg alb-IFN every 2 weeks (24 doses)+ Ribavirin 1000 or 1200 mg/day
Drug: albumin interferon alfa-2b
900 mcg or 1200mcg every two week for 48 weeks
Drug: Ribavirin

1000 mg/day(for subjects <75kg) or 1200 mg/day (for subjects

=,> 75kg)


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Diagnosis of chronic hepatitis C.
  • Liver biopsy performed within 2 years of Day 0 or during screening.
  • Infected with hepatitis C virus genotype 1.
  • Interferon alfa treatment naïve (ie, have never been treated with an interferon product).
  • Subjects are eligible to enter the study if they (or their partners) are not pregnant or nursing, are sterile, or of non childbearing potential, or are willing to practice abstinence or use appropriate birth control methods during the study and for 7 months after the last dose of ribavirin.
  • Have compensated liver disease.

Key Exclusion Criteria:

  • Decompensated liver disease including those subjects with a past history or presence of ascites, bleeding varices or hepatic encephalopathy.
  • History of moderate, severe or uncontrolled psychiatric disease, especially depression, including a history of hospitalization or prior suicidal attempt.
  • Positive for human immunodeficiency virus (HIV-1) or hepatitis B surface antigen (HBsAG).
  • Clinical diagnosis of other causes of chronic liver disease including but not limited to hepatitis B, autoimmune hepatitis, primary biliary cirrhosis, alcoholic liver disease, hemochromatosis, Wilson's Disease, or alpha 1-antitrypsin deficiency.
  • A history of immunologically mediated disease (eg, rheumatoid arthritis, inflammatory bowel disease, moderate/severe psoriasis, sarcoidosis, systemic lupus erythematosus).
  • Active seizure disorder within the last 2 years.
  • Organ transplant other than cornea and hair transplant.
  • Clinically significant hemoglobinopathy (eg, thalassemia, sickle cell anemia).
  • Cancer within the last 5 years(with the exception of adequately treated basal cell carcinoma of the skin or in situ carcinoma of the uterine cervix).
  • Drug or alcohol addiction within the last 6 months. Subjects in a supervised methadone treatment program may be enrolled in the study.
  • Received any experimental agent within 28 days prior to Day 0.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00402428

  Show 165 Study Locations
Sponsors and Collaborators
Human Genome Sciences Inc.
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Human Genome Sciences Inc. Identifier: NCT00402428     History of Changes
Other Study ID Numbers: HGS1008-C1060, ACHIEVE-1
Study First Received: November 20, 2006
Last Updated: August 1, 2013
Health Authority: Australia: Department of Health and Ageing Therapeutic Goods Administration
Australia: Human Research Ethics Committee
Austria: Agency for Health and Food Safety
Austria: Ethikkommission
Canada: Ethics Review Committee
Canada: Health Canada
Czech Republic: State Institute for Drug Control
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
France: National Consultative Ethics Committee for Health and Life Sciences
Germany: Ethics Commission
Germany: Federal Institute for Drugs and Medical Devices
India: Institutional Review Board
Israel: Ministry of Health
Italy: Ethics Committee
Italy: National Monitoring Centre for Clinical Trials - Ministry of Health
Poland: Ministry of Health
Romania: National Medicines Agency
Spain: Spanish Agency of Medicines
Switzerland: Ethikkommission
Switzerland: Swissmedic
United Kingdom: Medicines and Healthcare Products Regulatory Agency
United Kingdom: Research Ethics Committee
United States: Food and Drug Administration
United States: Institutional Review Board

Keywords provided by Human Genome Sciences Inc.:
Chronic Hepatitis C
Hepatitis C
Genotype 1

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Hepatitis, Chronic
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Peginterferon alfa-2a
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on November 20, 2014